Recent Progress on Therapeutic Vaccines for Breast Cancer
Breast cancer remains the most frequently diagnosed malignancy worldwide. Advanced breast cancer is still an incurable disease mainly because of its heterogeneity and limited immunogenicity. The great success of cancer immunotherapy is paving the way for a new era in cancer treatment, and therapeuti...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.905832/full |
| _version_ | 1828516803750395904 |
|---|---|
| author | Lianru Zhang Xipeng Zhou Huizi Sha Li Xie Baorui Liu |
| author_facet | Lianru Zhang Xipeng Zhou Huizi Sha Li Xie Baorui Liu |
| author_sort | Lianru Zhang |
| collection | DOAJ |
| description | Breast cancer remains the most frequently diagnosed malignancy worldwide. Advanced breast cancer is still an incurable disease mainly because of its heterogeneity and limited immunogenicity. The great success of cancer immunotherapy is paving the way for a new era in cancer treatment, and therapeutic cancer vaccination is an area of interest. Vaccine targets include tumor-associated antigens and tumor-specific antigens. Immune responses differ in different vaccine delivery platforms. Next-generation sequencing technologies and computational analysis have recently made personalized vaccination possible. However, only a few cases benefiting from neoantigen-based treatment have been reported in breast cancer, and more attention has been given to overexpressed antigen-based treatment, especially human epidermal growth factor 2-derived peptide vaccines. Here, we discuss recent advancements in therapeutic vaccines for breast cancer and highlight near-term opportunities for moving forward. |
| first_indexed | 2024-12-11T18:31:59Z |
| format | Article |
| id | doaj.art-ca7a629105064ee8966ddabc86ad5ebc |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T18:31:59Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ca7a629105064ee8966ddabc86ad5ebc2022-12-22T00:54:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-06-011210.3389/fonc.2022.905832905832Recent Progress on Therapeutic Vaccines for Breast CancerLianru Zhang0Xipeng Zhou1Huizi Sha2Li Xie3Baorui Liu4The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, ChinaDepartment of oncology, Yizheng People’s Hospital, Yangzhou, ChinaThe Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, ChinaThe Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, ChinaThe Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, ChinaBreast cancer remains the most frequently diagnosed malignancy worldwide. Advanced breast cancer is still an incurable disease mainly because of its heterogeneity and limited immunogenicity. The great success of cancer immunotherapy is paving the way for a new era in cancer treatment, and therapeutic cancer vaccination is an area of interest. Vaccine targets include tumor-associated antigens and tumor-specific antigens. Immune responses differ in different vaccine delivery platforms. Next-generation sequencing technologies and computational analysis have recently made personalized vaccination possible. However, only a few cases benefiting from neoantigen-based treatment have been reported in breast cancer, and more attention has been given to overexpressed antigen-based treatment, especially human epidermal growth factor 2-derived peptide vaccines. Here, we discuss recent advancements in therapeutic vaccines for breast cancer and highlight near-term opportunities for moving forward.https://www.frontiersin.org/articles/10.3389/fonc.2022.905832/fullbreast cancercancer vaccinescancer immunotherapyclinical trialsconcurrent therapies |
| spellingShingle | Lianru Zhang Xipeng Zhou Huizi Sha Li Xie Baorui Liu Recent Progress on Therapeutic Vaccines for Breast Cancer Frontiers in Oncology breast cancer cancer vaccines cancer immunotherapy clinical trials concurrent therapies |
| title | Recent Progress on Therapeutic Vaccines for Breast Cancer |
| title_full | Recent Progress on Therapeutic Vaccines for Breast Cancer |
| title_fullStr | Recent Progress on Therapeutic Vaccines for Breast Cancer |
| title_full_unstemmed | Recent Progress on Therapeutic Vaccines for Breast Cancer |
| title_short | Recent Progress on Therapeutic Vaccines for Breast Cancer |
| title_sort | recent progress on therapeutic vaccines for breast cancer |
| topic | breast cancer cancer vaccines cancer immunotherapy clinical trials concurrent therapies |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.905832/full |
| work_keys_str_mv | AT lianruzhang recentprogressontherapeuticvaccinesforbreastcancer AT xipengzhou recentprogressontherapeuticvaccinesforbreastcancer AT huizisha recentprogressontherapeuticvaccinesforbreastcancer AT lixie recentprogressontherapeuticvaccinesforbreastcancer AT baoruiliu recentprogressontherapeuticvaccinesforbreastcancer |